GENE ONLINE|News &
Opinion
Blog

2020-09-18| Asia-Pacific

Eisai Enters Vietnam With a Subsidiary

by Sahana Shankar
Share To

Japanese pharma Eisai Co., Ltd announced a pharmaceutical sales subsidiary in Ho Chi Minh, Vietnam on September 14, 2020. With Vietnam emerging as a sizeable market within South East Asia, the pharmaceutical market clocked in +10.6% compound annual growth from 2014 to 2019.

By Sahana Shankar, Ph.D. Candidate

The expected growth rate is estimated to continue in double digits for the coming years, owing to the expansion of middle-income groups and an increase in non-communicable diseases.

Eisai (Thailand) Marketing Co., Ltd operated in Vietnam through a local agency since 1992. In 1995, Eisai established a representative office in Ho Chi Minh City, with proton-pump inhibitor Pariet, muscle relaxant Myonal, peripheral neuropathy drug Mathylcobal, among others.

With Eisai Vietnam, Eisai targets enhanced sales in Vietnam and the delivery of innovative drugs to patients. Eisai launched a new anti-epileptic drug Fycompa in 2019 and has anti-cancer agents, Lenvima and Halaven at different regulatory processes levels.

Eisai Co., Ltd is a pharmaceutical company headquartered in Tokyo, Japan, with a global network of 10,000 employees, R&D facilities, manufacturing, and marketing subsidiaries focusing on neurology and oncology products.

Related Article: Eisai Obtains Novel Anti-Cancer Molecules via PRISM BioLab Contract

Reference:

https://www.eisai.com/news/2020/news202055.html

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Japan’s Gaia BioMedicine Teams Up With TreeFrog Therapeutics To Advance NK-Like Cell Therapies
2023-02-17
Eisai and Biogen’s Alzheimer’s Med, Leqembi, Granted FDA Approval
2023-01-09
Eisai Touts Lenvima Efficacy In Thyroid Cancer Study
2022-10-24
LATEST
Kite’s Yescarta Yields a Success in a Phase 3 Trial for Treating Large B-Cell Lymphoma
2023-03-22
Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
2023-03-22
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
2023-03-21
Comparing ESG Regulations in the U.S., the U.K., and the EU
2023-03-21
See-Mode Technologies Secures Regulatory Approvals for its AI-powered Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans in Australia and New Zealand
2023-03-21
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
2023-03-21
Scroll to Top